Heart Drug's nerve protection put to the test in real patients
NCT ID NCT06393465
Summary
This study looked back at existing medical records to see if a high dose of the drug tafamidis (Vyndamax) could slow down nerve damage in people with a specific type of heart disease called mixed-phenotype ATTR-CM. It involved 50 adults who had already been taking the drug for at least a year. Researchers compared their nerve function before and after starting treatment to measure its real-world effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.